离离子重塑与在实验性充血性心力衰竭的恢复期间维持心房动的能力之间的解离
Tae-Joon Cha1, Joachim R Ehrlich, Liming Zhang
15000 Belanger St East, Montreal, Quebec, H1T 1C8, Canada. nattel@icm.umontreal.ca
Circulation
|January 14, 2004
概括
充血性心力衰竭导致离子和结构重塑,导致心房动. 虽然心力衰竭治疗后的离子变化逆转了,但结构重塑仍然存在,这表明它在维持心房动方面发挥了主要作用.
科学领域:
- 心脏病学 心脏病学
- 电力生理学 电力生理学
- 心脏衰竭研究研究
背景情况:
- 充血性心力衰竭 (CHF) 诱导心房电生理学和结构的显著变化,称为离子和结构重塑.
- 这些重塑过程,包括改变的离子通道功能和增加的心房纤维化,都与心房的发展和维持有关.
- 在CHF的背景下,离子与结构改造对AF的相对贡献仍然是研究的主题.
研究的目的:
- 在实验性充血性心力衰竭 (CHF) 中研究离子和结构重塑的可逆性.
- 为了确定反向重塑对心房动 (AF) 基质的影响.
- 阐明负责CHF中AF维护的主要机制 (离子与结构).
主要方法:
- 在狗中,通过心室快速移动诱导了充血性心力衰竭 (CHF).
- 评估了血液动力学,心声学和电生理学参数,包括心房肌细胞离子电流和爆发节奏诱导的AF (DAF) 持续时间.
- 对心房组织进行了纤维化分析,并在没有节拍的恢复期后评估了变化.
主要成果:
- CHF导致关键心房电流 (I,to,I,Ks,I,Ca,L) 的显著下调和I,NCX的上调,同时增加了心房纤维化和延长的DAF.
- 经过一段恢复期后,血液动力学功能和所有测量的离子电流密度都恢复到了控制水平.
- 尽管离子重塑完全恢复,心房纤维化和延长的AF基质仍然存在,表明结构重塑没有恢复.
结论:
- 逆转CHF导致离子重塑完全恢复,但没有结构重塑 (心房纤维化).
- 在CHF逆转后,持续的结构改造和延长的AF基质表明它是维持AF的关键因素.
- 这些发现强调了结构改造是实验性CHF中AF维护的主要驱动因素,而不是离子改造.
相关概念视频
01:19Electrophysiology of Normal Cardiac Rhythm
The normal cardiac rhythm is a synchronized electrical activity that facilitates the regular and coordinated contraction of the heart muscle. This process is essential for efficient blood circulation throughout the body. The fundamental elements involved in establishing and maintaining this rhythm include the unique electrical properties of cardiac muscle cells, the sinoatrial (SA) node's pacemaker function, the specialized conducting system, and the ionic mechanisms underlying each phase of...
01:28Mechanism of Cardiac Arrhythmias
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...